Schedule
New Patients Referring Physicians
Find a Doctor
Patient Portal
Log In Enroll
Careers
Locations
1-888-663-3488
English
English Spanish
Donate

Department Metrics

View the grants, clinical trials and publications from the Tumor Microenvironment and Metastasis Department.

  • Grants

    • Moffitt Cancer Center Support Grant Years 24-27
      Award Number:
      Sponsor: Nat Institutes of Health
      PI:Cleveland, J.
    • Characterization and Targeting of the Epigenetic state underlying uveal melanoma liver metastasis
      Award Number:
      Sponsor: Nat Institutes of Health
      PI (MPI):Smalley, K.
    • State of Florida Appropriation
      Award Number:
      Sponsor: State of Florida
      PI:Cleveland, J.
    • Defining and Targeting Epigenetic Plasticity-Driven Drug Resistance and Immune Escape in Melanoma
      Award Number:
      Sponsor: Nat Institutes of Health
      PI (Contact):Smalley, K.
    • Role of ULK3 in Sensitive and Refractory Multiple Myeloma
      Award Number:
      Sponsor: Nat Institutes of Health
      PI:Lynch, C.
    • Uncovering Causal Protein Markers to Improve Prostate Cancer Etiology Understanding and Risk Prediction in Africans and Europeans
      Award Number:
      Sponsor: Nat Institutes of Health
      PI:Wang, L.
    • Epigenetic mechanisms that underlie breast cancer dormancy
      Award Number:
      Sponsor: Amer Cancer Society
      PI (Contact):Gomes, A.
    • Modulating dendritic cell (DC) polarization and biology with L-fucose to enhance DC vaccine efficacy
      Award Number:
      Sponsor: Florida Biomedical Research Program (FBRP)
      PI:Le-Lau, E.
    • Identifying How HDAC Suppression of SLC17A7 Drives Osteosarcoma Progression and Metastasis
      Award Number:
      Sponsor: Florida Biomedical Research Program (FBRP)
      PI:Lynch, C.
    • Proprietary arginine vasopressin receptor type 1a (AVPR1a) antagonists for treatment of lethal prostate cancer
      Award Number:
      Sponsor: US Army
      PI:Lynch, C.
    • Epigenetic Changes as a Biomarker in African Americans with Papillary Renal Cell Carcinoma and a Link to the Tumor Microenvironment
      Award Number:
      Sponsor: US Army
      PI:Wang, L.
    • Role of CRTC1-MAML2 in Salivary Mucoepidermoid Carcinoma Pathobiology
      Award Number:
      Sponsor: Nat Institutes of Health
      PI:Amelio, A.
    • SOW for project management, alliance management, and Executive Sponsors in Major Alliance with Turnstone
      Award Number:
      Sponsor: Turnstone Biologics
      PI:Cleveland, J.
    • Extending experimental evolutionary game theory in cancer in vivo to enable clinical translation: integrating spatio-temporal dynamics using mathematical modeling
      Award Number:
      Sponsor: Nat Institutes of Health
      PI:Marusyk, A.
    • Epigenetic and Metabolic Bottlenecks of Tumorigenesis
      Award Number:
      Sponsor: Nat Institutes of Health
      PI (Contact):Gomes, A.
    • Dissecting Tumor-Immune Interactions in HIV-HPV Co-Infection-Associated Oropharyngeal Cancer using Single Cell Sequencing and Novel Mouse Models
      Award Number:
      Sponsor: Nat Institutes of Health
      PI:Amelio, A.
    • Metabolic factors that condition breast cancer metastasis
      Award Number:
      Sponsor: Florida Biomedical Research Program (FBRP)
      PI (Contact):Gomes, A.
    • Optimizing immunotherapy strategies for melanoma brain metastases
      Award Number:
      Sponsor: Florida Biomedical Research Program (FBRP)
      PI (Contact):Smalley, K.
    • Proteolysis targeting chimera against nuclear receptor NR4A1 for melanoma therapy
      Award Number:
      Sponsor: Nat Institutes of Health
      PI (MPI):Smalley, K.
    • Characterization of Plant-Based Phenolic Alkanones as Next-Generation Sun Protectants for Skin Cancer Prevention
      Award Number:
      Sponsor: US Army
      PI (Contact):Premi, S.
    • Optimizing the immune mediated-destruction of NRAS mutant melanoma
      Award Number:
      Sponsor: Melanoma Research Alliance (MRA)
      PI (Contact):Smalley, K.,PI:Jaeger, A.
    • AGING AS A SELECTIVE PRESSURE THAT DRIVES TUMOR PROGRESSION
      Award Number:
      Sponsor: Nat Institutes of Health
      PI:Gomes, A.

  • Publications

    • Nasr MM, Wadie B, Li T, Frieling JS, du Bois H, Bishop RT, Tauro M, Malik B, Nyman KJ, Lynch CC. PRDM16 Regulates Prostate Cancer Cell Dormancy and Prevents Bone Metastatic Outgrowth. Cancer Res. 2026 Feb.86(3):604-621. Pubmedid: 41105683. Pmcid: PMC12862344.
    • Chaudhary R, Moorhead G, Park R, Li J, Schell MJ, Song X, Tan A, Slebos RJC, Biernacki MI, Freeman SS, Thatikonda S, Meshkovska Y, Hernandez-Prera J, Kirtane K, Guevara-Patino JA, Amelio AL, Rocco JW, Danysh BP, Bonomi M, Saba NF, Haradhvala NJ, Getz G, Chung CH. Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer. Clin Cancer Res. 2026 Feb.32(3):501-515. Pubmedid: 41117857. Pmcid: PMC12667737.
    • Hamaidi I, Cheng P, Jun SY, Manna A, Wang MH, Nguyen A, Can I, Zhang MG, Taylor OO, Bailon LUL, Fang B, Perez B, Creelan BC, Marusyk A, Shin D, Hwang TH, Berglund AE, Shapiro VS, Ji HM, Conejo-Garcia JR, Kim S. SIRT2-mediated deacetylation of LCK governs the magnitude of T cell receptor signaling. Nat Immunol. 2026 Feb.27(2):213-224. Pubmedid: 41611868. Pmcid: PMC12864039.
    • Srivastava J, Premi S. Melanin as a Redox Hub: Linking Energy Flow to Genome Stability and Immune Control. Antioxid Redox Signal. 2026 Feb.15230864261421542. Pubmedid: 41680087.
    • Solanki HS, Shah H, Imbody D, Desai B, Kato R, Miroshnychenko D, Stern YE, Majumder A, Sarcar B, Xieraili A, Stewart PA, Fang B, Zhang Y, Yao J, Darville LN, Koomen JM, Rix U, Evans JW, Yang YC, Ahler E, Marusyk A, Singh M, Aronchik I, Haura EB. RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer. Cancer Res. 2026 Jan.86(2):467-484. Pubmedid: 41165456.
    • Anastacio Da Costa Carvalho L, Tovbis Shifrin N, Phadke MS, Emmons MF, Pechuan-Jorge X, Mbuga F, Ospina OE, Chow C, Seu L, Rose OL, Hegde A, Khushalani NI, Quintana E, Smalley KSM. RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma. Cancer Immunol Res. 2026 Jan.14(1):90-106. Pubmedid: 41186497. Pmcid: PMC12666865.
    • Tian Y, McDonnell SK, Wu L, Larson NB, Wang L. Fine mapping regulatory variants by characterizing native CpG methylation with nanopore long-read sequencing. HGG Adv. 2026 Jan.7(1):100532. Pubmedid: 41109954. Pmcid: PMC12642126.
    • Hu Q, Remsing Rix LL, Desai B, Miroshnychenko D, Li X, Welsh EA, Fang B, Wright GM, Chaudhary N, Kroeger JL, Doebele RC, Koomen JM, Haura EB, Marusyk A, Rix U. Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling. Sci Signal. 2025 Dec.18(918):eads7662. Pubmedid: 41433419.
    • Morales MFG, Hogue SR, Pitcher S, Jeong D, Radosavljevic I, Stefanou A, Felder SI, Burns JR, Dowd SE, Vogtmann E, Sinha R, Wang L, Wang X, Permuth JB, Sears CL, Andersen SW, Greathouse KL, Kresovich JK, Friedman MS, Siegel EM, Byrd DA. Survival implications of the age-associated tumor and normal adjacent tissue microbiome among colorectal cancer patients. Gut Pathog. 2025 Dec.17(1):109. Pubmedid: 41437389. Pmcid: PMC12739855.
    • Avasthi KK, Manley BJ, Pellini B, Zhang J, Bloomer AM, Jean-Baptiste E, Marchion DC, Fang B, Koomen JM, Siegel EM, Wang L. Different plasma exosome isolation methods generated distinct microRNA and protein profiles in healthy controls and patients with advanced prostate and lung cancer. BMC Cancer. 2025 Dec.26(1):160. Pubmedid: 41469584. Pmcid: PMC12859987.
    • Zhong H, Zhu J, Liu S, Wu C, Wang L, Whelton SP, Marshall CH, Blaha MJ, Durda P, Guo X, Johnson CW, Lin HJ, Taylor KD, Tracy RP, Yarden RI, Manichaikul AW, Rich SS, Rotter JI, Deo R, Dubin RF, Ganz P, Wu L. Proteome-wide association study of prostate cancer risk across populations. Nat Commun. 2025 Dec. Pubmedid: 41353205.
    • Xu W, Zhang Q, Qiao L, Wang Z, Wang T, Dong D, Zhang Q, Wang L, Wei GH, Zhang P. IP-SNPs-seq links noncoding risk alleles to lineage transcription factor programs in prostate cancer. Cell Mol Life Sci. 2025 Dec.82(1):438. Pubmedid: 41359169. Pmcid: PMC12686227.
    • Yadav VK, Fang B, Koomen JM, Srivastava J, Premi S. Quantitative Proteomics of Nitrosylated Proteins in Melanoma Using the Biotin-Switch Technique Combined With Tandem Mass Tag Labeling. Bio Protoc. 2025 Dec.15(23):e5535. Pubmedid: 41377102. Pmcid: PMC12689159.
    • Wong J, Tian Y, Patel MS, Avasthi K, Hanson C, Larsen M, Ampaw E, Gutowski R, Fadlullah MZH, Finkelstein J, Tan AC, Park J, Manley BJ, Huang CC, Kohli M, Wang L. Plasma cell-free DNA methylation-based prognosis in metastatic castrate-resistant prostate cancer. NPJ Precis Oncol. 2025 Dec.10(1):29. Pubmedid: 41390880. Pmcid: PMC12816654.
    • Sultan M, Ma S, Diez J, Velayutham S, Al-Harbi Y, Choi JY, Smalley KSM, Nathanson L, Beljanski V, Minond D. Modulation of Spliceosomal Proteins hnRNPH1 and H2 Increases Melanoma Cell Pro-Inflammatory Signaling In Vitro. Biomolecules. 2025 Nov.15(11). Pubmedid: 41301529. Pmcid: PMC12649858.
    • Thatikonda S, Chaudhary R, Meshkovska Y, Biernacki M, Slebos RJC, Song X, Hall MS, Lilley K, Pilon-Thomas S, Guevara-Patino JA, Spiess PE, Chahoud J, Amelio AL, Wachter EA, Rodrigues D, Chung CH. PV-10 Triggers Immunogenic Cell Death in Head and Neck Squamous Cell Carcinoma via Endoplasmic Reticulum Stress and Apoptosis. Mol Cancer Ther. 2025 Nov.24(11):1733-1748. Pubmedid: 40552938. Pmcid: PMC12327362.
    • Beck R, Tagal V, Amin S, Bakhoum SF, Maley C, Verhaak RGW, Gomes AP, Andor N. Energetics of whole genome doubling and genomic instability. Cancer Lett. 2025 Oct.630:217878. Pubmedid: 40517938.
    • Lazure F, Gomes AP. Cancer progression through the lens of age-induced metabolic reprogramming. Nat Rev Cancer. 2025 Oct.25(10):801-817. Pubmedid: 40646271.
    • Dong D, Wang Z, Liu M, Zhang Q, Xu W, Wei Y, Zhu J, Yang X, Zhang Q, Zhu Y, Wang L, Zhang P, Wei GH. Combined SNPs sequencing and allele specific proteomics capture reveal functional causality underpinning the 2p25 prostate cancer susceptibility locus. Nat Commun. 2025 Oct.16(1):8950. Pubmedid: 41062477. Pmcid: PMC12508145.
    • Drapela S, Rad RC, Ilter D, Gomes AP. Protocol for the utilization of murine interstitial fluid extract to model breast cancer in the context of old age in vitro. STAR Protoc. 2025 Oct.6(4):104178. Pubmedid: 41171756. Pmcid: PMC12642106.
    • Hesterberg RS, Davis JT, Handoo KJ, Elmarsafawi AG, Augello AC, Cheng CH, Atkins R, Lee DH, Yang C, Yao J, Patel KR, Mediavilla-Varela M, Pinilla-Ibarz J, Soto-Palma C, Locke FL, Song X, Wang X, Berglund AE, Rodriguez PC, Knittel G, Flümann R, Reinhardt HC, Shaw TI, Yu X, Niedernhofer LJ, Cleveland JL. Lymphoma accelerates T cell and tissue aging. Cancer Cell. 2025 Oct.43(10):1917-1936.e8. Pubmedid: 40845845.
    • Park R, Rind F, Kristoff T, Li J, Schell M, Slebos RJC, Thatikonda S, Chaudhary R, Biernacki MI, Meshkovska Y, Kaldas D, Kim HS, Farinhas J, Hernandez-Prera J, Kirtane K, Hall MS, Amelio AL, Rocco JW, Bhateja P, Steuer C, Bonomi M, Saba NF, Chung CH. Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical Trial. Am J Clin Oncol. 2025 Sep. Pubmedid: 40905435.
    • Yadav VK, Srivastava J, Venkatachalam A, Tantak MP, Lawrence NJ, Fisher DE, Lawrence HR, Premi S. Melanin-Driven Delayed CPD Formation Is Independent of Melanin Biosynthesis Pathway. J Invest Dermatol. 2025 Sep. Pubmedid: 40992685. Pmcid: PMC12507450.
    • West J, Desai B, Strobl M, Gallaher J, Robertson-Tessi M, Marusyk A, Anderson ARA. Evolutionary antifragile therapy. bioRxiv. 2025 Sep. Pubmedid: 41000654. Pmcid: PMC12458151.
    • Sinawang PD, Multani P, Ozen MO, Wong J, Akin D, Hanson C, Larsen M, Ampaw E, Rondina MT, Tolley ND, Wang L, Cunningham BT, Kohli M, Demirci U. Plasma Preparation Strategies for Extracellular Vesicle-Based Biomarkers in Metastatic Castration-Resistant Prostate Cancer. J Extracell Biol. 2025 Aug.4(8):e70071. Pubmedid: 40755906. Pmcid: PMC12311838.
    • Milne A, Marusyk A, Maini PK, Anderson ARA, Picco N. The role of environmentally mediated drug resistance in facilitating the spatial distribution of residual disease. Commun Biol. 2025 Aug.8(1):1189. Pubmedid: 40783466. Pmcid: PMC12335614.
    • Phadke MS, Li J, Sriramareddy S, Rodriguez PC, Ruffell B, Luca VC, Tran TTT, Chen YA, Smalley KSM. Identification of anti-TIM-3 based checkpoint inhibitor combinations with activity in immunotherapy refractory melanoma models. J Immunother Cancer. 2025 Aug.13(8). Pubmedid: 40825611. Pmcid: PMC12366563.
    • Cole AR, Buj R, Uboveja A, Levasseur E, Wang H, Kedziora KM, Chatoff A, Huacachino AA, Marcinkiewicz MM, Amalric A, Yang B, Tangudu NK, Danielson J, Elwah A, White S, Li D, Wallace CT, Lazure F, Elishaev E, Borho L, Jazwinska DE, Laird MS, Atiya H, Bitler BG, Dangaj D, Coffman LG, Tseng G, Oesterreich S, Gomes AP, Gurkar AU, Schopfer FJ, Modugno F, Watkins SC, Zervantonakis IK, Stallaert W, Hempel N, Snyder NW, Aird KM. The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming. bioRxiv. 2025 Aug. Pubmedid: 40832218. Pmcid: PMC12363692.
    • Tauro M, Li T, Sudalagunta PR, Meads M, Canevarolo RR, Nerlakanti N, Alugubelli RR, Lawrence HR, Gunawan S, Ayaz M, Nareddy P, Yun SY, Shay G, Yang K, Tran TH, Bishop RT, Nasr MM, Lawrence NNJ, Schönbrunn E, Cleveland JL, Silva AS, Shain KH, Lynch CC. Unc-51 Like Kinase 3 (ULK3) is essential for autophagy and cell survival in multiple myeloma. Res Sq. 2025 Aug. Pubmedid: 40831505. Pmcid: PMC12363935.
    • Piña Y, Law V, Sahebjam S, Tran N, Siddarajappa N, Li J, Mo Q, Phadke MS, Arrington J, Macaulay R, Mokhtari S, Evernden B, Ahmed KA, Smalley I, Yu M, Smalley KSM, Forsyth PA. Phase IB Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD) from Solid Tumors: Results and Molecular Analyses. Neurooncol. 2025 Aug. Pubmedid: 40888040.
    • Thomas F, Capp JP, Dujon AM, Marusyk A, Asselin K, Campone M, Pujol P, Alix-Panabières C, Roche B, Ujvari B, Gatenby R, Nedelcu AM. Leveraging selection for function in tumor evolution: System-level cancer therapies. Evol Med Public Health. 2025 Aug.13(1):248-268. Pubmedid: 40979445. Pmcid: PMC12448390.
    • Liu S, Zhu J, Zhang H, Zhong H, Wong HTH, Wang L, Wu L. Causal Relationship Between Blood Metabolites and Prostate Cancer Risk: A Two-Sample Mendelian Randomization Study. Mol Carcinogen. 2025 Aug.64(8):1316-1329. Pubmedid: 40387704.
    • Musicant AM, Billington JMR, Damrauer JS, Modliszewski JL, Landuau LJB, Tsai YH, Mehta JH, Powers J, Betancourt R, Sekhri R, Padilla RJ, Hernandez-Prera JC, Hayes DN, Hackman TG, Gokcumen O, Knox SM, Amelio AL. An FGFR-p53 developmental signaling axis drives salivary cancer progression. Oncogene. 2025 Aug.44(32):2876-2892. Pubmedid: 40456865.
    • Musicant AM, Billington JMR, Damrauer JS, Modliszewski JL, Landau LJB, Tsai YH, Mehta JH, Powers J, Betancourt R, Sekhri R, Padilla RJ, Hernandez-Prera JC, Hayes DN, Hackman TG, Gokcumen O, Knox SM, Amelio AL. Correction: An FGFR-p53 developmental signaling axis drives salivary cancer progression. Oncogene. 2025 Aug.44(32):2924. Pubmedid: 40542202.
    • Echevarria M, Park R, Caudell JJ, Kim Y, Yang GQ, Kirtane K, Chaudhary R, Kumar S, Amelio AL, Giuliano AR, Chung CH. Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy. Cancer Res Commun. 2025 Jul.5(7):1194-1202. Pubmedid: 40643202. Pmcid: PMC12281097.
    • De Martino D, Zapatería B, Dunne JB, Drapela S, Matteson K, Oruko D, Humphrey T, Jonhston T, Varghese BA, Riggio AI, Tiwary K, Bresnahan E, Barra J, Sowa A, Jenssen W, Sidoli S, Welm AL, Barroso M, Stallaert W, Gomes AP, Angel PM, Arias E, Bravo-Cordero JJ. Collagen hydroxylation couples NAD+/NADH dynamics to tumor dormancy and reactivation. Res Sq. 2025 Jul. Pubmedid: 40671813. Pmcid: PMC12265173.
    • Yu X, Jain MD, Menges MA, Cen L, Noble JD, Atkins R, Mohammad TJ, Bachmeier CA, Naderinezhad S, Reid K, Corallo S, Yoder SJ, Zhang C, Zhang L, Miranda JA, Shah B, Chavez JC, Hesterberg RS, Delgado LC, Savid-Frontera C, Rodriguez PC, Cleveland JL, Wang X, Davila ML, Locke FL. Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing. J Immunother Cancer. 2025 Jul.13(7). Pubmedid: 40730421. Pmcid: PMC12306477.
    • Tyczynska Weh M, Kumar P, Marusyk V, Marusyk A, Basanta D. The adaptive state determines the impact of mutations on evolving populations. Proc Natl Acad Sci U S A. 2025 Jul.122(26). Pubmedid: 40569384. Pmcid: PMC12232665.
    • Xu X, Liu X, Dollar JJ, Liu X, Jasani N, Posorske B, Sriramareddy SN, Jarajapu V, Kuznetsoff JN, Sinard J, Bennett RL, Licht JD, Smalley KSM, Harbour JW, Yu X, Karreth FA. A multi-step immune-competent genetic mouse model reveals phenotypic plasticity in uveal melanoma. bioRxiv. 2025 Jun. Pubmedid: 40502063. Pmcid: PMC12157397.
    • Srivastava J, Premi S. Targeting S-Nitrosylation to Overcome Therapeutic Resistance in NRAS-Driven Melanoma. Cancers (Basel). 2025 Jun.17(12). Pubmedid: 40563669. Pmcid: PMC12191001.
    • Bishop RT, Li T, Sudalagunta P, Nasr M, Nyman KJ, Alugubelli RR, Meads M, Frieling J, Nerlakanti N, Tauro M, Fang B, Grant S, Koomen J, Silva AS, Shain KH, Lynch CC. Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed/refractory multiple myeloma. Haematologica. 2025 Jun.110(6):1351-1367. Pubmedid: 39633543. Pmcid: PMC12130774.
    • Srivastava J, Yadav VK, Jimenez RV, Phadatare PR, Inamdar NA, Young MM, Bacchiocchi A, Halaban R, Fang B, Pulido AM, Tsai KY, Smalley KSM, Koomen JM, Rodriguez PC, Premi S. Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors. Cancer Res. 2025 Jun.85(12):2268-2287. Pubmedid: 40287947. Pmcid: PMC12167936.
    • Elkholi IE, Robert A, Malouf C, Wu JL, Kuasne H, Drapela S, Macleod G, Hébert S, Pacis A, Calderon V, Kleinman CL, Gomes AP, Alvarez JV, Aguirre-Ghiso JA, Park M, Angers S, Côté JF. Targeting the Dependence on PIK3C3-mTORC1 Signaling in Dormancy-Prone Breast Cancer Cells Blunts Metastasis Initiation. Cancer Res. 2025 Jun.85(12):2179-2198. Pubmedid: 40372253. Pmcid: PMC12167933.
    • Kleberg J, Nataraj A, Xiao Y, Podder BR, Jin Z, Tithi TI, Zheng G, Smalley KSM, Moser EK, Safe S, Maharjan CK, Kolb R, Zhang W. Targeting Lineage-Specific Functions of NR4A1 for Cancer Immunotherapy. Int J Mol Sci. 2025 May.26(11). Pubmedid: 40508074. Pmcid: PMC12155124.
    • Marusyk A. Evolutionary gambit to defeat drug resistance in cancer. Nat Biotechnol. 2025 May.43(5):689-690. Pubmedid: 38965429.
    • Sun Y, Zhu J, Zhong H, Zhang Z, Wang F, Nakamura A, Liu Y, Liu J, Yu J, Zeng G, Lin X, Zhou D, Wu C, Wang L, Deng Y, Wu L. Transcriptome-Wide Association Study Identified Novel Blood Tissue Gene Biomarkers for Prostate Cancer Risk. Prostate. 2025 May.85(6):567-579. Pubmedid: 39878408.
    • Ramamoorthi G, Lee MC, Farrell CM, Snyder C, Garg SK, Aldrich AL, Lok V, Dominguez-Viqueira W, Olson-Mcpeek SK, Rosa M, Gautam N, Pilon-Thomas S, Cen L, Kodumudi KN, Wiener D, Oskarsson T, Gomes AP, Gatenby RA, Czerniecki BJ. Antitumor CD4+ T Helper 1 Cells Target and Control the Outgrowth of Disseminated Cancer Cells. Cancer Immunol Res. 2025 May.13(5):729-748. Pubmedid: 40249209. Pmcid: PMC12046335.
    • Lee H, Shen J, Fadlullah MZ, Neibling A, Hanson C, Ampaw E, Lin T, Larsen M, Lloyd J, Maughan BL, Swami U, Gupta S, Tward J, Johnson SB, O'Neil B, Schmidt B, Dechet CB, Haaland B, Wang L, Tan AC, Kohli M. Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer. Clin Proteomics. 2025 Apr.22(1):13. Pubmedid: 40251526. Pmcid: PMC12008844.
    • Wong J, Tian Y, Patel MS, Avasthi K, Hanson C, Larsen M, Ampaw E, Fadlullah MZH, Finklestein J, Tan AC, Park J, Manley BJ, Huang CC, Kohli M, Wang L. Plasma Cell-Free DNA Methylation-Based Prognosis in Metastatic Castrate-Resistant Prostate Cancer. Res Sq. 2025 Apr. Pubmedid: 40313768. Pmcid: PMC12045346.
    • Desai B, Miti T, Prabhakaran S, Miroshnychenko D, Henry M, Marusyk V, Kumar P, Ozakinci H, Gatenbee C, Bui M, Boyle TA, Scott J, Altrock PM, Haura E, Anderson ARA, Basanta D, Marusyk A. Multifactorial stroma-mediated resistance is a major contributor to residual disease under targeted therapies in lung cancers. Res Sq. 2025 Apr. Pubmedid: 40313737. Pmcid: PMC12045365.
    • Renatino Canevarolo R, Sudalagunta PR, Meads MB, Silva M, Zhao X, Magaletti D, Alugubelli RR, DeAvila G, Persi E, Maura F, Bell ET, Bishop RT, Cubitt CL, Sansil SS, Zhang W, Teer JK, Teng M, Yoder SJ, Siegel EM, Shah BD, Nishihori T, Hazlehurst LA, Lynch CC, Landgren O, Hampton O, Gatenby RA, Sullivan DM, Brayer JB, Dalton WS, Cleveland JL, Alsina M, Baz R, Shain KH, Silva AS. Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma. Res Sq. 2025 Apr. Pubmedid: 40321765. Pmcid: PMC12048002.
    • Drapela S, Garcia BM, Gomes AP, Correia AL. Metabolic landscape of disseminated cancer dormancy. Trends Cancer. 2025 Apr.11(4):321-333. Pubmedid: 39510896. Pmcid: PMC11981868.
    • Nowicka Z, Rentzeperis F, Tagal V, Teer JK, Ilter D, Beck RJ, Cole JP, Forero Pinto AM, Tejero JD, Scanu E, Veith T, Dominguez-Viqueira W, Maksin K, Carrillo-Perez FM, Gevaert O, Xu X, Karreth FA, Abdalah MA, Fiandaca G, Pasetto S, Prabhakaran S, Schultz A, Ojwang' AME, Barnholtz-Sloan JS, Farinhas JM, Gomes AP, Katira P, Andor N. Interactions between Ploidy and Resource Availability Shape Clonal Evolution in Glioblastoma. Cancer Res. 2025 Apr.85(8):1544-1559. Pubmedid: 39933186.
    • Rogina B, Anderson R, Lebrasseur N, Curan S, Yousefzadeh MJ, Ghosh B, Duque G, Howlett S, Austad S, Demuth I, Gerstorf D, Korfhage J, Lombard DB, Abadir P, Christensen K, Carey JR, Alberts SC, Campos F, Palavicini JP, Palmer A, Bell J, Basisty N, de Cabo R, Gomes A, Dixit VD, Sen P, Baur JA, Imai SI, Li X, Valdez G, Orr ME, Pletcher S, Andersen J, Jones L, Castillo-Azofeida D, Bonaguidi M, Suh Y, Duncan FE, Murray A, Wang MC, Burkewitz K, Henne M, Zhou K, Bouhrara M, Benjamini D, Kolind S, Walker KA, Reiter DA, Dean Iii D, Gorbunova V, Gladyshev VN, Palovics R, Niedernhofer LJ, Fan R, Bueckle AD, Hurley J, Esser KA, Kapahi P, Sato S, Jiang N, Ashiqueali SA, Diaz J, Mishra SP, Ralmundo N, Banarjee R, Allsopp R, Reynolds LM, Zhang B, Sebastiani P, Monti S, Schork N, Rappaport N. Symposia Report of The Annual Biological Sciences Section Meeting of the Gerontological Society of America 2023, Tampa, Florida. J Gerontol A-Biol. 2025 Apr.80(5). Pubmedid: 39932386. Pmcid: PMC12046124.
    • Maranto C, Udhane V, Jia J, Verma R, Müller-Newen G, LaViolette PS, Pereckas M, Sabharwal L, Terhune S, Pattabiraman N, Njar VCO, Imig JD, Wang L, Nevalainen MT. Correction: Maranto et al. Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers 2020, 12, 3412. Cancers (Basel). 2025 Mar.17(6). Pubmedid: 40149386. Pmcid: PMC11940198.
    • Kato R, Solanki HS, Ozakinci H, Desai B, Gundlapalli H, Yang YC, Aronchik I, Singh M, Johnson J, Marusyk A, Boyle TA, Haura EB. In Situ RAS:RAF Binding Correlates with Response to KRASG12C Inhibitors in KRASG12C-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2025 Mar.31(6):1150-1162. Pubmedid: 39836411. Pmcid: PMC11924342.
    • Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalainen MT, Patel M, Wong J, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L. 5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies. Commun Med (Lond). 2025 Mar.5(1):61. Pubmedid: 40038525. Pmcid: PMC11880319.
    • Fadlullah MZH, Nix D, Herberts C, Maurice-Dror C, Wyatt AW, Schmidt B, Fairbourn B, Tan AC, Wang L, Kohli M. Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer. JNCI Cancer Spectr. 2025 Mar.9(2). Pubmedid: 40036789. Pmcid: PMC11954629.

Cambiar el idioma

Si no encuentra la información que busca o si desea programar una cita, llámenos gratis al 1-888-663-3488.

Gracias.

 

 

 

 

Cancel | Cancelar OK